EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Rainmed Medical Ltd (2297) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Rainmed Medical Ltd HK$0.02, price HK$0.16, upside -89.0%, quality 21 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK

RM Thin data Sep 27, 2026

Rainmed Medical Ltd

2297 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$0.0170 · Strongly overvalued (−89.0%)
!Quality 21/100
!Weak Growth (revenue 5y +25.8 %/yr)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Rainmed Medical Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$5.28 HK$0.1300 Fair Value HK$0.0170 Jul 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

51‑month range HK$0.1300 – HK$5.28 · fair‑value band HK$0.0085 – HK$0.0170 · the HK$0.1550 price screens above the HK$0.0170 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Rainmed Medical in your weekly email

Every Wednesday you see whether Rainmed Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rainmed Medical Limited operates as a vascular interventional surgical robotics company in China and internationally.

Show more

Rainmed Medical Limited operates as a vascular interventional surgical robotics company in China and internationally. It engages in the research and development, manufacturing, and commercialization of medical instruments related to coronary angiography-derived fractional flow reserve (caFFR) systems and coronary angiography-derived index of microvascular resistance (caIMR) systems. The company also offers FlashAngio caFFR System, a coronary angiography-derived fractional flow reserve measurement system; FlashAngio caIMR System, which provides auxiliary diagnosis of coronary artery diseases; and disposable blood pressure transducer, which is used in conjunction with specialized equipment. In addition, it provides reagents and others installation and training services. Rainmed Medical Limited was founded in 2014 and is headquartered in Suzhou, China.

Stock analysis

Rainmed Medical Ltd (2297) currently trades at HK$0.1550, while our model-based Fair Value estimate is HK$0.0170, 89.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$0.0085 (bear) to HK$0.0170 (bull), the price of HK$0.1550 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Rainmed Medical Ltd reported revenue of 19.2M CNY in FY2025 versus 81.2M CNY in FY2021, a compound −30.3%/yr. Reported net income was −77.1M CNY in FY2025.

Key figures

Market cap HK$336M (≈ $42.9M) · P/S ratio 17.5 · EPS (TTM) HK$−0.0300 · Return on equity −20.7% · Return on assets (EBIT) −21.1% · Operating margin −443% · Revenue (TTM) 19.2M CNY · Revenue growth (YoY) −32.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −89%, 2297 screens richer than that median.

Fair Value models

Bear HK$0.0085 Fair Value HK$0.0170 Bull HK$0.0170
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) HK$0.1500 HK$0.2000 HK$0.3000 54
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.1500 HK$0.2000 HK$0.3000 54

Open the full fair value analysis →

Notify me when 2297 reaches fair value

Put 2297 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 21/100

Of which business quality 24 · Market factors (momentum, volatility) 16

Profitability 1
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 72
Disciplined investing over empire-building
Low Volatility 51
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−51.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.8%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−530.7% (2020) → −413.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2297 screens overvalued: fair value 89% below the price. Compare with Abbott Laboratories, →

Compare Rainmed Medical Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −89.0% · Bottom 25%
Profitability
Return on assets −9.3% · Below median
Growth and dividend
Revenue growth −32.3% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.12× · Cheapest 25%
P/S (TTM) 2.24× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 4
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 8
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.29 $74.79 −26%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.92 $48.31 +10%
Edwards Lifesciences Corporation EW $86.29 $81.94 −5%
Siemens Healthineers AG SHL €37.79 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rainmed Medical Ltd · Fair Value
HK$0.0170 −89%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Rainmed Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2297

Frequently asked questions

Is Rainmed Medical Ltd (2297) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.0170 versus a price of HK$0.1550, about −89% upside (overvalued).
What is the fair value of 2297?
Our model-based fair value for Rainmed Medical Ltd is HK$0.0170 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.1550.
What is the quality score of 2297?
Rainmed Medical Ltd has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rainmed Medical Ltd (2297)?
Our model-based price target is the fair value of HK$0.0170 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.0085, optimistic scenario HK$0.0170. It is a calculation from audited fundamentals, not an analyst target.
What is the Rainmed Medical Ltd stock forecast for 2026?
Our models put fair value at HK$0.0170, about −89% upside versus a price of HK$0.1550 (overvalued). Cautious scenario HK$0.0085, optimistic scenario HK$0.0170. The calculation is refreshed regularly with new filings.
What is the revenue of Rainmed Medical Ltd (2297)?
Rainmed Medical Ltd reported trailing-twelve-month revenue of about 19.2M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Rainmed Medical Ltd (2297)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rainmed Medical Ltd it is HK$0.0170 per share (as of Sep 27, 2026), against a price of HK$0.1550. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Rainmed Medical Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2297 trades above its calculated fair value: price HK$0.1550, fair value HK$0.0170, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2297?
No. The price is what the market pays today (HK$0.1550); the fair value is what the company's own numbers justify (HK$0.0170). For Rainmed Medical Ltd the two are HK$0.1380 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rainmed Medical Ltd worth?
The market values Rainmed Medical Ltd at about HK$336M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.1550; our models calculate a fair value of HK$0.0170 per share.
What do the bullish and bearish scenarios say about 2297?
Our models span a range for Rainmed Medical Ltd: cautious scenario HK$0.0085, base HK$0.0170, optimistic HK$0.0170 per share (as of Sep 27, 2026, price HK$0.1550). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rainmed Medical Ltd (2297)?
Balance-sheet figures for Rainmed Medical Ltd (as of Sep 27, 2026): return on equity −20.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is 2297 from its 52-week high?
Rainmed Medical Ltd trades at HK$0.1550, about 55% below its 52-week high of HK$0.3450 and 3% above the low of HK$0.1500 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0170 is for.
Which stocks are comparable to Rainmed Medical Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rainmed Medical Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.1550, calculated fair value HK$0.0170 (−89%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2297 calculated?
We run Rainmed Medical Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.0170, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Rainmed Medical Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rainmed Medical Ltd (2297)?
The closing price on Sep 30, 2026 was HK$0.1550. Our model-based fair value is HK$0.0170, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rainmed Medical Ltd right now?
The price sits above even our optimistic bull case (HK$0.0170). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.0085 to HK$0.0170) leaves room in how you read the outcome.

Key figures of Rainmed Medical Ltd

How large is the market capitalisation of Rainmed Medical Ltd (2297)?
The market capitalisation of Rainmed Medical Ltd is HK$336M (≈ $42.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rainmed Medical Ltd (2297)?
The price-to-sales ratio of Rainmed Medical Ltd is 17.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rainmed Medical Ltd (2297)?
Earnings per share at Rainmed Medical Ltd are HK$−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rainmed Medical Ltd (2297)?
The return on equity (ROE) of Rainmed Medical Ltd is −20.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rainmed Medical Ltd (2297)?
On an EBIT basis the return on assets of Rainmed Medical Ltd is −21.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rainmed Medical Ltd (2297)?
The operating margin of Rainmed Medical Ltd is −443% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rainmed Medical Ltd (2297)?
Revenue at Rainmed Medical Ltd is growing −32.3% versus a year earlier (3y avg −38.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rainmed Medical Ltd (2297) generate?
The free cash flow of Rainmed Medical Ltd is −79.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rainmed Medical Ltd (2297) carry?
The net debt of Rainmed Medical Ltd is 10.4M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rainmed Medical Ltd in the live analysis

One click puts Rainmed Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.